In March, AACR's journals editors highlighted studies on the development of pediatric leukemia, the use of low-dose tamoxifen, and more.
Relacorilant was approved for previously treated ovarian, fallopian tube, and peritoneal cancers. The U.S. Food and Drug Administration (FDA) has approved relacorilant (Lifyorli) in combination with nab-paclitaxel for the treatment of platinum-resistant epithelial ovarian,...
Therapy may reduce a chemotherapy-induced platelet disorder, and PSMA PET scans may help people with suspected prostate cancer forgo a biopsy.
Learn about smoldering myeloma and the first treatment approved by the U.S. Food and Drug Administration to prevent its progression to active multiple myeloma. Circulating throughout our bodies are various types of immune cells...
Treatment regimen approved for multiple myeloma, and people with melanoma who undergo sentinel node biopsy live longer.
Some people with prostate cancer may not need hormone therapy, and colorectal cancer cases shift increasingly to younger adults.
The FDA has approved teclistamab with daratumumab hyaluronidase-fihj for certain patients with pretreated multiple myeloma. The U.S. Food and Drug Administration (FDA) approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj (Darzalex Faspro) for adult...
Epidemiologist Elizabeth A. Platz explains what goes into calculating cancer risk estimates, such as rate ratio, hazard ratio, and absolute risk.
The FDA has converted the accelerated approval of encorafenib and cetuximab plus chemotherapy to full approval for first-line treatment of certain colorectal cancers. The U.S. Food and Drug Administration (FDA) has granted traditional approval...
First tumor treating fields device for pancreatic cancer approved, and hair extension products often contain potentially dangerous chemicals.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More